First-line (1L) trastuzumab deruxtecan (T-DXd)–based regimens in advanced HER2-expressing gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): Safety results from DESTINY-Gastric03 (DG-03) Part 2 arms D and F, and Part 4.
Yelena Y. Janjigian(Memorial Sloan Kettering Cancer Center), J I Lee(Samsung Medical Center), Roy Rabbie(AstraZeneca (Poland)), Bogusława Karaszewska(State University of Applied Sciences in Konin), Caron Lloyd(AstraZeneca (Netherlands)), Aitana Calvo Ferrándiz(Hospital General Universitario Gregorio Marañón), Megan Scott(AstraZeneca (Singapore)), Eric Xueyu Chen(University Health Network), Tianshu Liu(Sun Yat-sen University), Hirokazu Shoji(National Cancer Center Hospital East), Eric Nwazue(AstraZeneca (Netherlands)), Keun-Wook Lee(Seoul National University Bundang Hospital), Filippo Pietrantonio(Fondazione IRCCS Istituto Nazionale dei Tumori), M. Luisa Limon(Hospital Universitario Virgen del Rocío), Sun Young Rha(Yonsei University), Hanneke W.M. Van Laarhoven(Amsterdam University Medical Centers), Kohei Shitara(National Cancer Center Hospital East), Kathia Cristina Abdalla(Hospital de Base), Jamil Asselah(McGill University Health Centre), Anna Kowalczyk(University Clinical Centre)
Cited by 0
Related Papers
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
|New England Journal of Medicine|2019|1.4k